The TGF-βR1 inhibitor galunisertib re-shapes the PDAC-TME by limiting decidual-like natural killer cells polarization
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
Research suggests that the TGF-βR1 inhibitor galunisertib may impact the tumor microenvironment in pancreatic cancer. The role of certain cells and molecules, including decidual-like natural killer cells and CCL3, is being studied in relation to the treatment's effectiveness. The treatment's response may be predicted by specific factors, including the presence of LIF-producing macrophages in basal-like pancreatic cancer.